[Edaily Reporter Kim Hyung-il ] Access Bio, Inc.(950130)has signed a supply contract with a subsidiary of U.S. consumer goods company Procter & Gamble (P&G) for self-test kits capable of simultaneously diagnosing influenza and COVID-19. The contract is valued at 5 billion won, equivalent to 15.9% of last year’s revenue.

According to the Financial Supervisory Service’s electronic disclosure system on the 20th, Access Bio, Inc. announced that it had signed a supply contract with The Procter & Gamble Manufacturing Company in the U.S. to provide home test kits capable of simultaneously diagnosing influenza A and B and COVID-19. The confirmed contract amount is 4.96607 billion won, representing 15.89% of last year’s consolidated revenue of 31.25511 billion won. The contracting party is an unlisted subsidiary of P&G, and its separate revenue figures were not disclosed.

The contract period runs through October 14 of next year. The supply region is the United States, and Access Bio, Inc. will manufacture and supply the products in-house. Payment is due within 120 days of the invoice date.

The contract amount was calculated based on the minimum purchase commitment. The contract value in U.S. dollars is $3,728,000, which was converted to Korean won using the official exchange rate of 1,332.10 won per dollar published by the Seoul Foreign Exchange Brokerage on the 20th, the date of the disclosure. Accordingly, the won-denominated amount may vary depending on future exchange rate fluctuations.

This contract involves the supply of at-home diagnostic kits capable of testing for both the flu and COVID-19 simultaneously. However, specific details such as the supply volume or unit prices per product were not disclosed.